Article Text

PDF
Aortic disease: thoracic endovascular aortic repair
  1. Colin Bicknell1,
  2. Janet T Powell2
  1. 1Department of Surgery & Cancer, Imperial College London, St Mary's Hospital, London, UK
  2. 2Department of Surgery & Cancer, Imperial College London, Charing Cross Hospital, London, UK
  1. Correspondence to Professor Janet T Powell or Colin Bicknell, Department of Surgery & Cancer, Imperial College London, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, UK; j.powell{at}imperial.ac.uk or colin.bicknell{at}imperiam.ac.uk

Abstract

Following the first reported case of thoracic endovascular aortic repair (TEVAR) in 1987, there has been rapid technological development and widespread uptake of this approach for thoracic aortic disease. TEVAR has particular advantages for acute thoracic syndromes and there is continuing development of TEVAR for use in the elective situation. This is still a young technology and many unknowns remain, including long-term outcomes and the relative advantages and disadvantages versus both conservative treatment and open surgical repair. The current uses of TEVAR in the treatment of aortic dissection, thoracic aortic aneurysm, penetrating aortic ulcer and trauma are discussed.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.